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Joubert syndrome (JBTS) is a primarily autosomal-recessive disorder characterized by a distinctive mid-hindbrain and cerebellar malfor-
mation, oculomotor apraxia, irregular breathing, developmental delay, and ataxia. JBTS is a genetically heterogeneous ciliopathy. We
sought to characterize the genetic landscape associated with JBTS in the French Canadian (FC) population. We studied 43 FC JBTS sub-
jects from 35 families by combining targeted and exome sequencing. We identified pathogenic (n ¼ 32 families) or possibly pathogenic
(n ¼ 2 families) variants in genes previously associated with JBTS in all of these subjects, except for one. In the latter case, we found a
homozygous splice-site mutation (c.735þ2T>C) in CEP104. Interestingly, we identified two additional non-FC JBTS subjects with mu-
tations inCEP104; one of these subjects harbors a maternally inherited nonsensemutation (c.496C>T [p.Arg166*]) and a de novo splice-
site mutation (c.25722A>G), whereas the other bears a homozygous frameshift mutation (c.1328_1329insT [p.Tyr444fs*3]) in CEP104.
Previous studies have shown that CEP104 moves from the mother centriole to the tip of the primary cilium during ciliogenesis. Knock-
down of CEP104 in retinal pigment epithelial (RPE1) cells resulted in severe defects in ciliogenesis. These observations suggest that
CEP104 acts early during cilia formation by regulating the conversion of the mother centriole into the cilia basal body. We conclude
that disruption of CEP104 causes JBTS. Our study also reveals that the cause of JBTS has been elucidated in the great majority of our
FC subjects (33/35 [94%] families), even though JBTS shows substantial locus and allelic heterogeneity in this population.Joubert syndrome (JBTS [MIM: 213300]) is a predomi-
nantly autosomal-recessive disorder characterized by
oculomotor apraxia, hypotonia, neonatal breathing abnor-
malities, ataxia, and variable developmental delay. The
hallmark of JBTS is a malformation involving the brain-
stem and cerebellum and consisting of cerebellar vermis
hypoplasia or aplasia, horizontal elongated cerebellar pe-
duncles, and a deep interpeduncular fossa; together, these
take on the pathognomonic appearance of a ‘‘molar
tooth.’’1 A subset of individuals with JBTS also have extra-
neural manifestations such as polydactyly, retinopathy,
cystic kidneys, and liver fibrosis (reviewed by Romani
et al.2).
JBTS is a ciliopathy, given that themajority of the known
genes associated with JBTS have been shown to play a role
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extracellular membrane and functions as an antenna by
sensing extracellular signals and transducing them intra-
cellularly. The cilium is composed of a microtubule-based
cytoskeleton called the axoneme, which nucleates from
the basal body, a modified centriolar structure. At the
base of the cilium, Y-shaped structures connect the basal
body to the cell membrane, forming the transition zone,
which constitutes a diffusion barrier between the cilium
and the remainder of the plasma membrane (for a review,
see Valente et al.3). The majority of genes associated with
JBTS encode proteins that localize to the basal body or
ciliary transition zone. Many of these proteins physically
interact with one another to form large complexes. The
most important complex in the pathogenesis of JBTS is
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which 9 of its known 15members are associated with JBTS,
Meckel syndrome (MKS [MIM: 249000]), and/or oral-
facial-digital syndrome (OFD [MIM: 311200]).4–7 MKS
and OFD are related ciliopathies whose features overlap
those of JBTS.
Although JBTS was first described in a French Canadian
(FC) family in 1969,8 little is known about its molecular eti-
ology in this population. We thus sought to characterize
the genetic landscape associated with JBTS in the FC pop-
ulation by studying a large number of unrelated families.
Using a stepwise approach of targeted and whole-exome
sequencing (WES), we were able to explain most cases
and show that mutations in CEP104 cause JBTS.
This study was approved by our institutional ethics
committee. Informed consent was obtained from all partic-
ipants or their legal guardians. We identified 43 FC individ-
uals with JBTS (from 35 families). All individuals are of FC
ancestry and originate from various regions throughout
Quebec. The diagnosis of JBTS was based on the presence
of (1) at least one JBTS classical neurological manifestation
(oculomotor apraxia, ataxia, or history of breathing abnor-
malities) and (2) the molar tooth sign (MTS) on brain im-
aging in at least one affected family member (Figure S1).
In addition, four fetuses were included in the study. On
prenatal imaging, all fetal subjects showed cerebellar ver-
mis hypoplasia or aplasia and elongated cerebellar pedun-
cles, suggestive of JBTS.
We previously explained JBTS in 21 of these individuals
(15 families), who showed pathogenic mutations in
C5orf42 (MIM: 614571), TMEM231 (MIM: 614949), or
CC2D2A (MIM: 612013)9,10 (see Table S1). In JBTS-affected
individuals from the FC population, these studies estab-
lished the presence of a complex founder effect involving
three recurrent mutations in C5orf42 (c.4006C>T
[p.Arg1336Trp], c.7400þ1G>A, and Ensembl transcript
ENST00000509849, c.4690G>A [p.Ala1564Thr] [Gen-
Bank: NM_023073.3]), two recurrent mutations in
CC2D2A (c.3376G>A [p.Glu1126Lys] and c.4667A>T
[p.Asp1556Val] [GenBank: NM_001080522.2]), and two
recurrent mutations in TMEM231 (c.12T>A [p.Tyr4*] and
c.625G>A [p.Asp209Asn] [GenBank: NM_001077418.1]),
each of which was previously shown to be present on a
common haplotype (see Table S1).9,10 Thus, we used
Sanger sequencing to screen all unexplained JBTS-affected
families (n ¼ 19) for the seven known recurrent FC muta-
tions. Five individuals (fetus 474, 1673.590, 1951.677,
HSJ-JBTS-3, and HSJ-JBTS-4) were found to have homozy-
gous or compound-heterozygous mutations in C5orf42,
and two individuals (1342.488 and 1343.488) showed
compound-heterozygous mutations in CC2D2A (Table 1).
In addition, screening identified a single heterozygous mu-
tation in C5orf42 in one individual (2049.708) and single
heterozygous mutations in CC2D2A in two individuals
(1610.572 and 1123.415). Sequencing the remaining
exons of C5orf42 in individual 2049.708 revealed a hetero-
zygous truncating variant (c.6354dupT [p.Ile2119Tyrfs*2]
[GenBank: NM_023073.3]), whereas sequencing the re-The Americanmaining exons of CC2D2A in individuals 1610.572 and
1123.415 identified a heterozygous canonical splice-site
variant (c.2181þ1G>A [GenBank: NM_001080522.2]) in
the former and a heterozygous missense variant
(c.3544T>C [p.Trp1182Arg]) in the latter (Table 1). The
c.3544T>C (p.Trp1182Arg) variant has been previously
reported as pathogenic in an individual with nephronoph-
thisis.11 These three individuals are compound heterozy-
gous for their respective mutations.
In parallel, disease in three individuals was elucidated on
a clinical basis. Two affected individuals were found to
have mutations in NPHP1 (MIM: 607100): individual
1712.604 showed a 0.152 Mb homozygous deletion en-
compassing NPHP1 on chromosomal microarray in region
2q13 (110,826,262–110,978,224; UCSC Genome Browser
hg19 assembly), and individual 1915.669 showed a homo-
zygous frameshift (c.555delA [p.Lys185Asnfs*7] [GenBank:
NM_207181.2]) in NPHP1. Parents were confirmed to be
heterozygous carriers of the mutations. Individual HSJ-
JBTS-1 showed a homozygous mutation (c.2132A>C [p.As-
p711Ala] [GenBank: NM_153704.5]) in TMEM67 (MIM:
609884). This mutation has been previously identified in
a French individual with JBTS.12
We then performedWES in the remaining eight individ-
uals (from seven families) in whom disease had not been
explained. Genomic DNA from each sample was captured
with the Agilent SureSelect 50 Mb exome capture oligonu-
cleotide library and sequenced with paired-end 100 bp
reads on an Illumina HiSeq 2000, resulting in an average
of 12.8 Gb of raw sequence for each sample. Exome capture
and sequencing were performed at the McGill University
and Ge´nome Que´bec Innovation Center (MUGQIC).
Data were analyzed as previously described.13 We aligned
reads to human genome assembly hg19 by using the Bur-
rows-Wheeler Aligner (BWA v.0.5.9) and then used Picard
(v.1.48) to remove putative PCR-generated duplicate reads.
The median read depth of bases in consensus coding
sequence (CCDS) exons was 1023 (determined with
Genome Analysis Toolkit v.1.6.7).14 On average, 91%
(53%) of bases in CCDS exons were covered by at least
20 reads. We used SAMtools (v.0.1.17) mpileup and
bcftools to call sequence variants and required at least
three variant reads andR20% variant reads for each called
position, as well as Phred-like quality scores of at least
20 for single-nucleotide variants (SNVs) and at least
50 for small insertions or deletions (indels). We used
ANNOVAR15 and custom scripts to annotate variants ac-
cording to the type of mutation, occurrence in dbSNP,
1000 Genomes minor allele frequencies, and NHLBI
Exome Sequencing Project (ESP) Exome Variant Server
(EVS) minor allele frequencies. To identify potentially
pathogenic variants, we filtered out (1) synonymous vari-
ants or intronic variants other than those affecting the
consensus splice sites, (2) variants seen in more than 5 of
1,128 exomes (sequenced at the MUGQIC) from individ-
uals with rare, monogenic diseases unrelated to JBTS, and
(3) variants with a minor allele frequency greater thanJournal of Human Genetics 97, 744–753, November 5, 2015 745
0.5% in either the 1000 Genomes or the NHLBI ESP exome
datasets.
We first looked at the exome datasets for rare variants
in the 23 genes already associated with JBTS (INPP5E
[MIM: 613037], TMEM216 [MIM: 613277], AHI1 [MIM:
608894], NPHP1, CEP290 [MIM: 610142], TMEM67,
RPGRIP1L [MIM: 610937], ARL13B [MIM: 608922],
CC2D2A, CXORF5 [OFD1; MIM: 300170], KIF7 [MIM:
611254], TCTN1 [MIM: 609863], TCTN2 [MIM: 613885],
TMEM237 [MIM: 614424], CEP41 [MIM: 610523],
TMEM138 [MIM: 614459], C5orf42, TMEM231, TCTN3
[MIM: 613847], ZNF423 [MIM: 604557], CSPP1 [MIM:
611654], B9D1 [MIM: 614209], KIAA0586 [MIM:
610178], MKS1 [MIM: 609883], B9D2 [MIM: 611951] and
C2CD3 [MIM: 615944]9,10,12,16–39), as well as the JBTS
candidate gene TTC21B (MIM: 612014).40
In one individual (1310.476), we identified homozygous
frameshift mutation c.555delA (p.Lys185Asnfs*7) (Gen-
Bank: NM_207181.2) in NPHP1; this is the same mutation
that was identified in individual 1915.669. However, array
genomic hybridization showed that this individual is also
heterozygous for a 116 kb deletion encompassing NPHP1
in chromosomal region 2q13 (110,862,369–110,978,000;
hg19 genome assembly). This deletion is similar to that
found in subject 1712.604. The mother is heterozygous
for the frameshift mutation, but paternal DNAwas unavai-
lable. It thus appears that the proband in this family is
compound heterozygous for mutations in NPHP1. The
presence of the same nonsense mutation and deletion in
NPHP1 in unrelated FC individuals represents another
example of a complex founder effect in this JBTS
population.
In another individual (1639.581), we identified com-
pound-heterozygousmutations in B9D1: a nonsensemuta-
tion (c.493C>T [p.Gln165*] [GenBank:NM_001243473.1])
and a missense mutation (c.151T>C [p.Ser51Pro] [Gen-
Bank: NM_015681.3]) predicted to be damaging (Table 1;
Table S1). These variants are both extremely rare given
that they are absent in the EVS. In a third individual
(1686.595), we identified a hemizygous c.920T>A (p.Va-
l307Asp) missense variant (GenBank: NM_003611.2) in
OFD1 on chromosome X. This missense change, which is
located in a coiled-coil domain, is predicted to be damaging
by PolyPhen-2 (score ¼ 0.804), SIFT (score ¼ 0.003), and
CADD (C score¼26.4) and is absent in the EVS. Segregation
studies were not performed because parental DNA was un-
available. It remains unclear whether this mutation is
pathogenic.
In thetwoaffectedsiblingsof family472,we identifiedcom-
pound-heterozygousmutations (GenBank:NM_001286577.1)
in C2CD3: a nonsense mutation (c.5929C>T [p.Arg1977*])
and a missense mutation (c.5227G>T [p.Gly1743Cys])
predicted to be damaging (Table 1; Table S1). This missense
mutation affects a conserved amino acid (including in
zebrafish) located in the fifth C2 domain (Figure S2). The
two siblings with C2CD3 mutations have a classical form
of JBTSwith severe global developmental delay butwithout746 The American Journal of Human Genetics 97, 744–753, Novembany extraneural manifestations. Mutations in C2CD3 have
previously been reported in only five individuals, who all
showed OFD-like phenotypes.41
In one fetus (HSJ-JBTS-2), we identified compound-het-
erozygous mutations (GenBank: NM_001082538.2) in
TCTN1: c.3422A>C and c.898C>T (p.Arg300*). The
splicing mutation, c.3422A>C, had previously been re-
ported to be causative for JBTS.42 In another fetus
(1767.621), we identified two rare compound-heterozy-
gous variants (GenBank: NM_025114.3) in CEP290:
missense mutation c.6401T>C (p.Ile2134Thr) and canon-
ical splice-site mutation c.41951G>A. This acceptor
splice-site mutation has been previously reported in a sub-
ject with a JBTS-related ciliopathy, Senior-Loken syndrome
(MIM: 610189), which is characterized by the presence of
nephrophthiasis and congenital Leber amaurosis.43 The
c.6401T>C (p.Ile2134Thr) missense mutation is predicted
to be damaging by PolyPhen-2 (score ¼ 0.964), SIFT (score
¼ 0.03), and CADD (C score ¼ 29). It affects an amino acid
that is perfectly conserved down to the lower vertebrates.
However, it is found at a minor allele frequency of 0.55%
(64/11,600) in the EVS and at a relatively high frequency
of 2.2% in in-house FC samples, suggesting that it is un-
likely to be pathogenic. Targeted sequencing did not
show any other rare variant in CEP290 or in the other
known genes previously associated with JBTS. Moreover,
multiplex ligation-dependent probe amplification did not
identify a deletion or duplication in CEP290. Subse-
quently, the mother became pregnant, and the second
fetus showed the same phenotype and genotype as
the proband. It is unclear whether the c.6401T>C
(p.Ile2134Thr) missense mutation is pathogenic, whether
these fetuses carry another yet unidentified mutation in
CEP290, or whether JBTS in this family is explained bymu-
tations in another gene.
Only one individual (1763.618) remained without caus-
ative or candidate variants in known genes previously asso-
ciated with JBTS, MKS, or OFD. We identified ten genes
containing rare homozygous or multiple heterozygous var-
iants in the exome of this subject (Table S2). For each of
these genes, we searched PubMed (by using the search
term ‘‘cilia’’ and the name of the gene of interest) to deter-
mine whether their products localize to the cilia or have a
role in cilia function or development. Only one of
these genes, CEP104, is known to be implicated in cilia
function.44–46 In subject 1763.618, CEP104 harbors a
homozygous splice-site variant (c.735þ2T>C [GenBank:
NM_014704.3]) affecting the canonical donor splice site
following exon 7; this site encodes part of a coiled-coil
domain (Figure 1A). This variant, which is absent in public
SNP databases (dbSNP, EVS, 1000 Genomes, and the ExAC
Browser) and 201 in-house FC control exomes, is predicted
by MutationTaster and Human Splicing Finder to abolish
the donor splice and thus most likely cause the skipping
of this exon. Sanger sequencing confirmed that this
mutation is homozygous in the affected individual and
heterozygous in the unaffected parents (Figure 1B). Thiser 5, 2015
Table 1. Clinical Characteristics of Previously Unpublished JBTS-Affected Individuals Included in This Study
Individual Gene Mutations Gender Age MTS OMA
Retinal
Involvement
Renal
Involvement
Fetus 474 C5orf42 c.[4006C>T];[6407del], p.[Arg1336Trp];[Pro2136Hisfs*31]a F 22 weeks þ NA  
HSJ-JBTS-3 C5orf42 homozygous c.4006C>T (p.Arg1336Trp) F 28 years þ þ f h
HSJ-JBTS-4 C5orf42 homozygous c.4006C>T (p.Arg1336Trp) F 3 years þ þ þf u
1712.604 NPHP1 homozygous deletion of NPHP1 F 2 years þ þ e u
1915.669 NPHP1 homozygous c.555delA (p.Lys185Asnfs*7) F 3 years þ þ f u
HSJ-JBTS-1 TMEM67 homozygous c.2132A>C (p.Asp711Ala) F 3.5 years þ þ f u
1123.415 CC2D2A c.[3544T>C];[4667A>T], p.[Trp1182Arg];[Asp1556Val] F 4 years þ þ f u
1673.590 C5orf42 homozygous c.4006C>T (p.Arg1336Trp) F 12 years þ þ f u
1951.677 C5orf42 c.[4006C>T];[7400þ1G>A], p.[Arg1336Trp];[?] F 1 years þ þ þe u
1342.488 CC2D2A c.[4667A>T];[3376G>A], p.[Asp1556Val];[Glu1126Lys] M 28 years þ þ f h
1343.488 M 31 years þ þ f h
2049.708 C5orf42 c.[4690G>A];[6354dupT], p.[Ala1564Thr];[Ile2119Tyrfs*2] F 1.5 years þ  f u
1610.572 CC2D2A c.[4667A>T];[2181þ1G>A], p.[Asp1556Val];[?] F 2 years þ þ e u
1310.476 NPHP1 hemizygous c.555delA (p.Lys185Asnfs*7),
NPHP1 deletion
M 18 years þ þ f þu
HSJ-JBTS-2 TCTN1 c.[3422A>C];[898C>T], p.[?];[Arg300*] M 27 weeks þ NA NA u
1639.581 B9D1 c.[493C>T];[151T>C], p.[Gln165*];[Ser51Pro] M 22 years þ þ f h
1767.621 CEP290 c.[6401T>C];[41951G>A], p.[Ile2134Thr];[?] F 21 weeks þ NA NA þ u
Fetus2 621 F 20 weeks þ NA NA þ u
1686.595 OFD1 hemizygous c.920T>A (p.Val307Asp) M 15 years þ þ þfb þu
1299.472 C2CD3 c.[5929C>T];[5227G>T], p.[Arg1977*];[Gly1743Cys] M 7 years þ  f u
1294.472 M 4 years þ þ e u
1763.618 CEP104 homozygous c.735þ2T>C F 2 years þ þ þe u
GeneDx01 CEP104 c.[25722A>G];[496C>T], p.[?];[Arg166*] F 2.5 years þ þ f u
842629 CEP104 homozygous c.1328_1329insT (p.Tyr444fs*3) M 3.5 years þ þ  
All individuals, except for GeneDx01 and 842629, are of French Canadian ancestry. Individuals 1342.488 and 1343.288 are siblings, as are 1299.472 and
1294.47. The following abbreviations are used: ADHD, attention deficit and hyperactivity disorder; e, electroretinogram; F, female; f, fundoscopy; h, history; ID,
intellectual disability; M, male; MTS, molar tooth sign; NA, not available or not applicable; OMA, oculomotor apraxia; u, ultrasound.
aThe genotype of the fetus was not tested but was assumed on the basis of the genotype of similarly affected sibling 1304.474 (Table S1).
bHypertensive retinopathy.
(Continued on next page)individual has a pure neurologic form of JBTS with a MTS
on brain imaging (Figure 1C), oculomotor apraxia, hypoto-
nia, and ataxia. She does not have breathing irregularities,
polydactyly, or retinal, renal, or liver involvement. She has
significant developmental delay given that she is not yet
sitting independently, nor is she saying any words at the
current age of 2.5 years (Table 1).
In a separate study, a 3.5-year-old Arab Israeli JBTS-
affected boy, who was born to consanguineous parents
(first cousins), was found to bear a homozygous frameshift
variant (c.1328_1329insT [p.Tyr444fs*3] [GenBank:The AmericanNM_014704.3]) in CEP104 (Figures 1A and 1B). This
variant was identified by exome capture (Agilent SureSelect
v.4) and paired-end 100 bp sequencing (HiSeq 2000)
initially done in both the affected individual and his unaf-
fected sister. Exome sequence analyses and rare-variant
filtering were performed as previously described.47
The mean coverage of the targeted exomes was 623, and
97% of bases were covered at R103. No rare recessive
(homozygous, hemizygous, or potentially compound-het-
erozygous) variants were identified in genes previously
associated with JBTS, OFD, or MKS in the exome of theJournal of Human Genetics 97, 744–753, November 5, 2015 747
Liver
Involvement
Limb
Anomalies
Developmental
Delay Cognition
Respiratory
Abnormality Hypotonia Ataxia Other
  NA NA NA NA NA 
h   borderline  þ þ strabismus
u þ þ NA  NA NA bifid epiglottis, strabismus, central polydactyly
on the right, bilateral preaxial poldaytyly in feet
u   NA   þ 
u  þ NA  þ NA 
u  þ mild ID  þ þ 
u  þ NA  þ þ 
u  þ mild ID  þ þ ADHD, motor apraxia
u  þ NA þ þ NA swallowing difficulties
h  þ moderate ID  þ þ autism, ADHD
h  þ normal
(university)
 þ þ 
u þ þ NA þ þ þ oromotor apraxia, swallowing difficulties, tongue
and hypothalamic hamartomas, neonatal seizures
u  þ NA  þ þ 
u  þ mild ID þ þ þ renal failure, renal transplant, severe dysphasia
u þ NA NA NA NA NA abnormal gyration of the frontal lobes
h   normal  þ þ congenital club feet, dysphasia
u þ NA NA NA NA NA occipital encephalocele, olfactory bulb agenesis,
bifid uterus, renal cysts
u  NA NA NA NA NA renal cysts
u  þ severe ID þ þ þ autism, end-stage renal failure, swallowing difficulties,
abdominal situs inversus
u  þ NA  þ þ 
u  þ NA þ þ þ swallowing difficulties, oromotor apraxia,
gastrostomy, fundoplication
u  þ NA þ þ þ 
u  þ NA    
u  þ severe ID  þ þ self-mutilation
Table 1. Continuedaffected individual. The c.1328_1329insT (p.Tyr444fs*3)
variant was confirmed by Sanger sequencing to be homo-
zygous in the affected subject but heterozygous in his un-
affected sister and parents. It is extremely rare in that it is
absent from public databases (dbSNP, 1000 Genomes,
EVS, and the ExAC Browser) and 350 in-house ethnically
matched exomes. Examination of high-quality SNPs in
the exome dataset indicated that this variant is located in
a homozygous region that spans at least 8 Mb (chr1:
1,653,004–9,777,599; hg19 genome assembly). Like sub-
ject 1763.618, this individual shows a pure neurologic748 The American Journal of Human Genetics 97, 744–753, Novembfrom of JBTS with oculomotor apraxia, profound psycho-
motor delay, self-mutilation, and a MTS on brain imaging
(Figure 1C).
In order to identify additional subjects with mutations
in CEP104, we sequenced its coding regions in a cohort
of 96 individuals with unexplained MKS but did not iden-
tify any candidate variants. We next queried CEP104 in
GeneMatcher, a freely accessible website that enables the
identification of individuals with variants in candidate
genes.48 We identified one gene match on the basis of an
entry deposited by the diagnostic laboratory GeneDx.er 5, 2015
AB
C
Figure 1. CEP104 Mutations in JBTS-Affected
Families
(A) Localization of the identified mutations in
CEP104 (upper panel) and CEP104 (lower panel;
925 amino acids). The coiled-coiled (CC) do-
mains (amino acid positions 209–289 and
677–725 according to UniProt: O60308) are
highlighted in yellow.
(B) Segregation of CEP104 mutations within
families.
(C) Brain MRI images of the JBTS individuals
with CEP104 mutations from family 618 (a
and a0), family A_I (b and b0), and GeneDx1 (c
and c0). Axial T1-weighted (a) and T2-weighted
(b and c) images show the molar tooth sign
with deepened interpeduncular fossa and elon-
gated, thickened, and abnormally orientated
superior cerebellar peduncles. Sagittal T1-
weighted images (a0, b0, and c’) show hypoplasia
of the cerebellar vermis (arrow).WES was performed and analyzed in this subject and his
unaffected parents on a clinical basis, as recently
described.49 The per-sample mean coverage of the target
exome was 1143, and 99.9% of bases were covered at
R103. This WES analysis showed two variants in
CEP104: c.496C>T (p.Arg166*) and c.25722A>G (Figures
1A and 1B). The c.496C>T variant is extremely rare in that
it has been reported at a MAF of 0.00015 (2/13,004) and
0.00002 (3/121,316) in the EVS and ExAC Browser, respec-
tively. The c.25722A>G variant, which is not reported in
the EVS or ExAC Browser, destroys the canonical splice
acceptor site of intron 20 (MutationTaster and Human
Splice Finder). This individual inherited the variant
c.496C>T (p.Arg166*) from his mother, whereas the
variant c.25722A>G occurred de novo. These results
were confirmed by Sanger sequencing. As predicted, this
individual (referred to herein as GeneDx01), a 28-month-
old white non-FC male, has a JBTS phenotype similar to
that of the FC and Arab Israeli individuals, including globalThe American Journal of Humandevelopmental delay, oculomotor apraxia,
and MTS on brain imaging (Figure 1C). He
has a pure neurologic phenotype with
absence of polydactyly, retinopathy, and
nephropathy (Table 1). Analysis of the
exome data did not reveal any other de
novo variants or rare recessive variants in
genes previously associated with JBTS,
MKS, or OFD. We were not able to phase
the de novo c.25722A>G variant by us-
ing the trio exome sequencing data
because of the absence of informative
markers in the region. However, it is
most likely that this variant is in trans
with the maternally inherited nonsense
variant, given that the majority (~76%)
of de novo point mutations arise in the
paternal germline.50 Moreover, de novo
mutations are rare events in that theaverage exome contains only zero to three such muta-
tions.51 The likelihood that a JBTS-affected individual
who does not show any rare variants in known ciliop-
athy-related genes carries a de novo mutation in cis with
a rare nonsense mutation in a strong candidate gene is
extremely low.
CEP104 localizes on both mother and daughter centri-
oles in non-ciliated retinal pigment epithelial (RPE1) cells
but only on the daughter centriole in ciliated cells.44–46
The mother centriole functions as a basal body by nucle-
ating cilia when the cells are in the G0 stage of the cell cy-
cle; upon re-entry to the division phase, cells resorb their
cilia, allowing the centrioles to form spindle poles. Inter-
estingly, CEP104 moves from the mother centriole to the
tip of the primary cilium during ciliogenesis.46 Moreover,
knockdown of CEP104 in RPE1 cells impairs ciliogene-
sis.45,46 Together, these observations suggest that loss of
CEP104 function affects ciliogenesis by disrupting the con-
version of the mother centriole into the ciliary basal body.Genetics 97, 744–753, November 5, 2015 749
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Figure 2. Locus and Allelic Heterogeneity of JBTS in FC Individuals
The graph shows the number of different alleles associated with JBTS in FC individuals. The total number (n) of JBTS-affected families
with mutations in the indicated genes is shown beneath the gene name. The number of families bearing the recurrent alleles is noted in
parentheses following the allele name on the x axis. Deletion 1 refers to chr2: 110,826,262–110,978,224, and deletion 2 refers to chr2:
110,862,369–110,978,000 (hg19 genome assembly).CEP104 is known to interact with the centriolar protein
complex CEP97-CP110, which inhibits ciliary assembly.52
Depletion of either CEP97 or CP110 promotes primary
cilia formation. It has been suggested that CEP104 might
be involved in the removal of the inhibitory complex
CP110-CEP97 from the mother centriole and thereby
allow its conversion into the basal body and the nucleation
of the cilia.46 Interestingly, CP110 suppresses the ability of
CEP290, a product of a gene associated with JBTS, to coop-
erate with RAB8A to enable cilia assembly.53,54 CP110 has
also been shown to interact with C2CD3 and KIAA0586,
other products of genes associated with JBTS.38,55
In summary,we identified rare and deleteriousmutations
inCEP104, a gene involved in ciliogenesis, in three individ-
uals with JBTS. The occurrence of such mutations in unre-
lated individuals strongly suggests that disruption of
CEP104 causes JBTS. In addition, our survey of the genetic
landscape associated with JBTS in the FC population re-
vealed great genetic heterogeneity with the possible
involvement of as many as 11 genes (Figures S3 and S4).
Of a total of 35 families, 14 are affected by causal mutations
in C5orf42, nine by mutations in CC2D2A, three by muta-
tions in NPHP1, two by mutations in TMEM231, and one
each by mutations in TCTN1, TMEM67, B9D1, C2CD3, or
CEP104 (Figure 2).We identified possible pathogenicmuta-750 The American Journal of Human Genetics 97, 744–753, Novembtions in CEP290 in one family and OFD1 mutations in
another. There is also significant allelic heterogeneity given
that a total of eight different mutations were identified in
C5orf42 and seven were identified in CC2D2A (Figure 2).
Finally, in FC JBTS-affected individuals, we observed the
presence of a complex founder effect whereby four genes
contained a total of nine recurrent mutations (Figure S4).
Previous studies have identified the underlying genetic eti-
ology in 41%–62% of affected individuals by screening
known genes associated with JBTS in large heterogeneous
JBTS populations.41,56 In the current study, disease in 94%
of the affected FC individuals (in 33/35 families) has been
explained. This greater diagnostic yield is possibly related
to the fact that we systematically studied an ethnically ho-
mogeneous population by usingWES. Althoughwe cannot
ruleout that JBTS inadditional FC individualswhohavenot
yet been examined is explained by mutations in other
genes, the genetic landscape of JBTS appears to be largely
elucidated in this population.Supplemental Data
Supplemental Data include four figures and two tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
2015.09.009.er 5, 2015
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